1
|
Zhao H, Ravn AK, Haibach MC, Engle KM, Johansson Seechurn CCC. Diversification of Pharmaceutical Manufacturing Processes: Taking the Plunge into the Non-PGM Catalyst Pool. ACS Catal 2024; 14:9708-9733. [PMID: 38988647 PMCID: PMC11232362 DOI: 10.1021/acscatal.4c01809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Revised: 05/10/2024] [Accepted: 05/15/2024] [Indexed: 07/12/2024]
Abstract
Recent global events have led to the cost of platinum group metals (PGMs) reaching unprecedented heights. Many chemical companies are therefore starting to seriously consider and evaluate if and where they can substitute PGMs for non-PGMs in their catalytic processes. This review covers recent highly relevant applications of non-PGM catalysts in the modern pharmaceutical industry. By highlighting these selected successful examples of non-PGM-catalyzed processes from the literature, we hope to emphasize the enormous potential of non-PGM catalysis and inspire further development within this field to enable this technology to progress toward manufacturing processes. We also present some historical contexts and review the perceived advantages and challenges of implementing non-PGM catalysts in the pharmaceutical manufacturing environment.
Collapse
Affiliation(s)
- Hui Zhao
- Sinocompound
Catalysts, Building C,
Bonded Area Technology Innovation Zone, Zhangjiagang, Jiangsu 215634, China
| | - Anne K. Ravn
- Department
of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Michael C. Haibach
- Process
Research and Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Keary M. Engle
- Department
of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | | |
Collapse
|
2
|
Kang G, Xiao LJ, Hesp KD, Huh CW, Lian Y, Richardson P, Schmitt DC, Hong K, Yu JQ. Synthesis of Highly Substituted Aminotetrahydropyrans Enabled by Stereospecific Multivector C-H Functionalization. Org Lett 2024; 26:2729-2732. [PMID: 37294050 PMCID: PMC11161171 DOI: 10.1021/acs.orglett.3c01439] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Highly substituted aminotetrahydropyrans were synthesized via sequential C-H functionalizations. The process was initiated with a Pd(II)-catalyzed stereoselective γ-methylene C-H arylation of aminotetrahydropyran, followed by α-alkylation or arylation of the corresponding primary amine. The initial γ-C-H (hetero)arylation was compatible with a range of aryl iodides containing various substituents and provided the corresponding products in moderate to good yields. The subsequent α-alkylation or arylation of the isolated arylated products proceeded with high diastereoselectivity to afford value-added disubstituted aminotetrahydropyrans.
Collapse
Affiliation(s)
- Guowei Kang
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Li-Jun Xiao
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Kevin D. Hesp
- Treeline Biosciences, 500 Arsenal St, 2 Floor, Watertown, Massachusetts 02472
| | - Chan Woo Huh
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Yajing Lian
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Paul Richardson
- Medicine Design, Pfizer Inc., San Diego, California 92121, United States
| | - Daniel C. Schmitt
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Kai Hong
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Jin-Quan Yu
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
3
|
Yang H, Yu H, Stolarzewicz IA, Tang W. Enantioselective Transformations in the Synthesis of Therapeutic Agents. Chem Rev 2023; 123:9397-9446. [PMID: 37417731 DOI: 10.1021/acs.chemrev.3c00010] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/08/2023]
Abstract
The proportion of approved chiral drugs and drug candidates under medical studies has surged dramatically over the past two decades. As a consequence, the efficient synthesis of enantiopure pharmaceuticals or their synthetic intermediates poses a profound challenge to medicinal and process chemists. The significant advancement in asymmetric catalysis has provided an effective and reliable solution to this challenge. The successful application of transition metal catalysis, organocatalysis, and biocatalysis to the medicinal and pharmaceutical industries has promoted drug discovery by efficient and precise preparation of enantio-enriched therapeutic agents, and facilitated the industrial production of active pharmaceutical ingredient in an economic and environmentally friendly fashion. The present review summarizes the most recent applications (2008-2022) of asymmetric catalysis in the pharmaceutical industry ranging from process scales to pilot and industrial levels. It also showcases the latest achievements and trends in the asymmetric synthesis of therapeutic agents with state of the art technologies of asymmetric catalysis.
Collapse
Affiliation(s)
- He Yang
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Hanxiao Yu
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Izabela A Stolarzewicz
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Wenjun Tang
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
- School of Chemistry and Material Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China
| |
Collapse
|
4
|
Mathur V, Alam O, Siddiqui N, Jha M, Manaithiya A, Bawa S, Sharma N, Alshehri S, Alam P, Shakeel F. Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents. Molecules 2023; 28:5860. [PMID: 37570832 PMCID: PMC10420935 DOI: 10.3390/molecules28155860] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Revised: 07/13/2023] [Accepted: 07/15/2023] [Indexed: 08/13/2023] Open
Abstract
This article sheds light on the various scaffolds that can be used in the designing and development of novel synthetic compounds to create DPP-4 inhibitors for the treatment of type 2 diabetes mellitus (T2DM). This review highlights a variety of scaffolds with high DPP-4 inhibition activity, such as pyrazolopyrimidine, tetrahydro pyridopyrimidine, uracil-based benzoic acid and esters, triazole-based, fluorophenyl-based, glycinamide, glycolamide, β-carbonyl 1,2,4-triazole, and quinazoline motifs. The article further explains that the potential of the compounds can be increased by substituting atoms such as fluorine, chlorine, and bromine. Docking of existing drugs like sitagliptin, saxagliptin, and vildagliptin was done using Maestro 12.5, and the interaction with specific residues was studied to gain a better understanding of the active sites of DPP-4. The structural activities of the various scaffolds against DPP-4 were further illustrated by their inhibitory concentration (IC50) values. Additionally, various synthesis schemes were developed to make several commercially available DPP4 inhibitors such as vildagliptin, sitagliptin and omarigliptin. In conclusion, the use of halogenated scaffolds for the development of DPP-4 inhibitors is likely to be an area of increasing interest in the future.
Collapse
Affiliation(s)
- Vishal Mathur
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; (V.M.); (N.S.); (M.J.); (A.M.); (S.B.)
| | - Ozair Alam
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; (V.M.); (N.S.); (M.J.); (A.M.); (S.B.)
| | - Nadeem Siddiqui
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; (V.M.); (N.S.); (M.J.); (A.M.); (S.B.)
| | - Mukund Jha
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; (V.M.); (N.S.); (M.J.); (A.M.); (S.B.)
| | - Ajay Manaithiya
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; (V.M.); (N.S.); (M.J.); (A.M.); (S.B.)
| | - Sandhya Bawa
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; (V.M.); (N.S.); (M.J.); (A.M.); (S.B.)
| | - Naveen Sharma
- Division of Bioinformatics, Indian Council of Medical Research, New Delhi 110029, India;
| | - Sultan Alshehri
- Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia
| | - Prawez Alam
- Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia;
| | - Faiyaz Shakeel
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia;
| |
Collapse
|
5
|
Ruck RT, Strotman NA, Krska SW. The Catalysis Laboratory at Merck: 20 Years of Catalyzing Innovation. ACS Catal 2022. [DOI: 10.1021/acscatal.2c05159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Rebecca T. Ruck
- Department of Process Research & Development, Merck & Co., Inc., Rahway, New Jersey07065, United States
| | - Neil A. Strotman
- Department of Pharmaceutical Sciences & Clinical Supplies, Merck & Co., Inc., Rahway, New Jersey07065, United States
| | - Shane W. Krska
- Chemistry Capabilities Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey07033, United States
| |
Collapse
|
6
|
Kolarovič A, Jakubec P. State of the Art in Crystallization‐Induced Diastereomer Transformations. Adv Synth Catal 2021. [DOI: 10.1002/adsc.202100473] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Andrej Kolarovič
- Department of Chemistry Faculty of Education Trnava University Priemyselná 4 918 43 Trnava Slovakia
| | - Pavol Jakubec
- Institute of Organic Chemistry Catalysis and Petrochemistry Slovak University of Technology Radlinského 9 812 37 Bratislava Slovakia
| |
Collapse
|
7
|
Ye F, Zhang Z, Zhao W, Ding J, Wang Y, Dang X. Two methods for the preparation of sitagliptin phosphate via chemical resolution and asymmetric hydrogenation. RSC Adv 2021; 11:4805-4809. [PMID: 35424414 PMCID: PMC8694546 DOI: 10.1039/d0ra10273c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Accepted: 12/26/2020] [Indexed: 01/20/2023] Open
Abstract
Two effective processes have been developed for the preparation of sitagliptin phosphate.
Collapse
Affiliation(s)
- Fei Ye
- School of Chemistry and Chemical Engineering
- Ningxia Normal University
- Guyuan
- China
| | - Zhifeng Zhang
- School of Chemistry and Chemical Engineering
- Ningxia Normal University
- Guyuan
- China
| | - Wenxia Zhao
- School of Chemistry and Chemical Engineering
- Ningxia Normal University
- Guyuan
- China
| | - Jianhai Ding
- School of Chemistry and Chemical Engineering
- Ningxia Normal University
- Guyuan
- China
| | - Yali Wang
- School of Chemistry and Chemical Engineering
- Ningxia Normal University
- Guyuan
- China
| | - Xueyan Dang
- School of Chemistry and Chemical Engineering
- Ningxia Normal University
- Guyuan
- China
| |
Collapse
|
8
|
Yoshimura T, Umeda Y, Takahashi R, Matsuo JI. Development of Nitrolactonization Mediated by Iron(III) Nitrate Nonahydrate. Chem Pharm Bull (Tokyo) 2020; 68:1220-1225. [PMID: 33268654 DOI: 10.1248/cpb.c20-00645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The nitrolactonization of alkenyl carboxylic acids mediated by Fe(NO3)3·9H2O has been developed. Nitrolactones were obtained in up to 93% yield by treatment of alkenyl carboxylic acids with Fe(NO3)3·9H2O. Mechanistic studies disclosed that the reaction proceeded through a radical intermediate generated from addition of NO2 to alkenyl carboxylic acids.
Collapse
Affiliation(s)
- Tomoyuki Yoshimura
- Division of Pharmaceutical Sciences, Graduate School of Medical Sciences, Kanazawa University
| | - Yuki Umeda
- Division of Pharmaceutical Sciences, Graduate School of Medical Sciences, Kanazawa University
| | - Risako Takahashi
- Division of Pharmaceutical Sciences, Graduate School of Medical Sciences, Kanazawa University
| | - Jun-Ichi Matsuo
- Division of Pharmaceutical Sciences, Graduate School of Medical Sciences, Kanazawa University
| |
Collapse
|
9
|
Peng F, Humphrey GR, Maloney KM, Lehnherr D, Weisel M, Lévesque F, Naber JR, Brunskill APJ, Larpent P, Zhang SW, Lee AY, Arvary RA, Lee CH, Bishara D, Narsimhan K, Sirota E, Whittington M. Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 2: Development of a Robust Process for Phenol Synthesis. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00241] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Feng Peng
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Guy R. Humphrey
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kevin M. Maloney
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Dan Lehnherr
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Mark Weisel
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Francois Lévesque
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - John R. Naber
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Andrew P. J. Brunskill
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Patrick Larpent
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Si-Wei Zhang
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Alfred Y. Lee
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Rebecca A. Arvary
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Claire H. Lee
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Daniel Bishara
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Karthik Narsimhan
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Eric Sirota
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael Whittington
- Small Molecule Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
10
|
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. JOURNAL OF NATURAL PRODUCTS 2020; 83:770-803. [PMID: 32162523 DOI: 10.1021/acs.jnatprod.9b01285] [Citation(s) in RCA: 2966] [Impact Index Per Article: 741.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
This review is an updated and expanded version of the five prior reviews that were published in this journal in 1997, 2003, 2007, 2012, and 2016. For all approved therapeutic agents, the time frame has been extended to cover the almost 39 years from the first of January 1981 to the 30th of September 2019 for all diseases worldwide and from ∼1946 (earliest so far identified) to the 30th of September 2019 for all approved antitumor drugs worldwide. As in earlier reviews, only the first approval of any drug is counted, irrespective of how many "biosimilars" or added approvals were subsequently identified. As in the 2012 and 2016 reviews, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions, and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/or synthetic variations using their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from 1946 to 1980, of the 75 small molecules, 40, or 53.3%, are N or ND. In the 1981 to date time frame the equivalent figures for the N* compounds of the 185 small molecules are 62, or 33.5%, though to these can be added the 58 S* and S*/NMs, bringing the figure to 64.9%. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures, though as can be seen in the review there are still disease areas (shown in Table 2) for which there are no drugs derived from natural products. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are still able to identify only two de novo combinatorial compounds (one of which is a little speculative) approved as drugs in this 39-year time frame, though there is also one drug that was developed using the "fragment-binding methodology" and approved in 2012. We have also added a discussion of candidate drug entities currently in clinical trials as "warheads" and some very interesting preliminary reports on sources of novel antibiotics from Nature due to the absolute requirement for new agents to combat plasmid-borne resistance genes now in the general populace. We continue to draw the attention of readers to the recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated"; thus we consider that this area of natural product research should be expanded significantly.
Collapse
Affiliation(s)
- David J Newman
- NIH Special Volunteer, Wayne, Pennsylvania 19087, United States
| | - Gordon M Cragg
- NIH Special Volunteer, Gaithersburg, Maryland 20877, United States
| |
Collapse
|
11
|
Sivák I, Toběrný M, Kyselicová A, Caletková O, Berkeš D, Jakubec P, Kolarovič A. Stereoselective Synthesis of Functionalized α-Amino Acids Isolated by Filtration. J Org Chem 2018; 83:15541-15548. [DOI: 10.1021/acs.joc.8b02647] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Ivan Sivák
- Institute of Organic Chemistry, Catalysis and Petrochemistry, Slovak University of Technology, Radlinského 9, Bratislava 812 37, Slovakia
| | - Michal Toběrný
- Institute of Organic Chemistry, Catalysis and Petrochemistry, Slovak University of Technology, Radlinského 9, Bratislava 812 37, Slovakia
| | - Andrea Kyselicová
- Institute of Organic Chemistry, Catalysis and Petrochemistry, Slovak University of Technology, Radlinského 9, Bratislava 812 37, Slovakia
| | - Ol’ga Caletková
- Institute of Organic Chemistry, Catalysis and Petrochemistry, Slovak University of Technology, Radlinského 9, Bratislava 812 37, Slovakia
| | - Dušan Berkeš
- Institute of Organic Chemistry, Catalysis and Petrochemistry, Slovak University of Technology, Radlinského 9, Bratislava 812 37, Slovakia
| | - Pavol Jakubec
- Institute of Organic Chemistry, Catalysis and Petrochemistry, Slovak University of Technology, Radlinského 9, Bratislava 812 37, Slovakia
| | - Andrej Kolarovič
- Department of Chemistry, Faculty of Education, Trnava University, Priemyselná 4, Trnava 918 43, Slovakia
| |
Collapse
|